CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
SANTA CLARA, Calif., Sept. 15, 2016 -- Miramar Labs, Inc., (OTCQB:MRLB), a global aesthetic company, announced today that the Company will present at the Ladenburg Thalmann Healthcare Conference in New York, NY.
Event: Ladenburg Thalmann 2nd Annual Healthcare Conference
Date: Tuesday, September 27th, 2016
Time: 1:00 p.m. ET
An audio webcast of the Company’s presentation will be available online at www.miramarlabs.com/investors. A replay of the presentation will be available for 90 days.
Investors who are not attending the conference but would like to schedule a one-on-one meeting with Miramar management may do so by contacting Chris Nardo at The Ruth Group at [email protected].
About Miramar Labs:
Miramar Labs, Inc.® is a global medical device company dedicated to bringing innovative and clinically proven applications to treat unmet needs in the aesthetic marketplace. Supported by rigorous clinical research, Miramar Labs is focused on addressing medical conditions for which there are significant unmet clinical needs. The company’s first priority is the treatment of bothersome underarm sweat, an issue that hundreds of millions of people deal with daily. The miraDry® procedure has an established safety and efficacy profile with over 70,000 patients treated worldwide. Physicians and patients are encouraged to visit www.miramarlabs.com or www.miradry.com for additional information.
Contact: Investors: Brigid Makes Sr. Vice President & CFO Phone: 408.579.8700 Email: [email protected] Nick Laudico or Zack Kubow The Ruth Group 646-536-7030 / 7020 [email protected] [email protected]
